UKAS ISO 15189

NewGene participates in both national and international external quality assessment programmes.

Its laboratory has received UKAS accreditation to ISO 15189 Medical Laboratories for the following tests:

Molecular Pathology

  • BRAF targeted mutation detection (colorectal cancer, hairy cell leukaemia and melanoma)
  • EGFR targeted mutation detection (non-small-cell lung cancer)
  • RAS targeted mutation detection in colorectal tumours including KRAS and NRAS genes

Molecular Haematology

  • BCR-ABL monitoring in chronic myeloid leukaemia
  • cKIT targeted mutation analysis (mastocytosis and acute myeloid leukaemia)
  • JAK2, MPL and calreticulin targeted mutation detection in myeloproliferative neoplasms
  • TPMT genotyping

Molecular Genetics

  • Breast cancer: Full gene sequencing of the BRCA1 and BRCA2 genes
  • Noonan spectrum disorders: Full gene sequencing for the following genes - PTPN11, SPRED1, KRAS, SOS1, RAF1, NRAS, BRAF, SHOC2 (exon 1 only), MAP2K1, MAP2K2, HRAS, CBL , NF1, RIT1 and A2ML1
  • Familial hypercholesterolaemia targeted mutation detection in genes APOB, PCSK9 and LDLR

Cick here to view Newgene’s Schedule of Accreditation

Care Quality Commission


NewGene participates in the following external quality assessment programmes.

UK NEQAS for Molecular Genetics:

  • Next generation sequencing
  • BRCA1 and BRCA2 sequencing
  • KRAS
  • EGFR
  • BRAF
  • GIST (new pilot)

Cick here to view Newgene’s Schedule of Accreditation

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne

Tel: +44 (0)191 241 8769
Fax: +44 (0)191 241 8799
Email: info@newgene.org.uk

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience


Sophia Genetics



Enquiry form